Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and ...

A common option that’s used to primarily alleviate mild joint pain and stiffness is known as a nonsteroidal anti-inflammatory drug (NSAID). Unlike acetaminophen, which only relieves pain ...

A six-month course would cost $12,522 while the drug would cost $48,696 for patients who need to stay on it for 18 months. There’s no definite cut-off point for treatment, although, the label ...

More than 50% of patients with severe asthma have high eosinophil levels, making them candidates for biologic therapies like Nucala and other drugs like AstraZeneca’s Fasenra (benralizumab ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...